(Bloomberg) -- Illumina Inc. and activist investor Carl Icahn tried but failed to reach a compromise that would have avoided the public battle over seats on its board, according to a preliminary proxy statement filed by the DNA-sequencing company.Most Read from BloombergTrump Faces Fingerprints, Mug Shot After Dramatic IndictmentSingapore’s Changi Sees Immigration System Restored After Delays$335,000 Pay for ‘AI Whisperer’ Jobs Appears in Red-Hot MarketA $3 Trillion Threat to Global Financial Ma
Francis deSouza was awarded $26.7mn in total pay last year despite drop in genome sequencer’s market value
Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.